Complex formation between VEGFR2 and the β2-adrenoceptor

Kilpatrick, Laura E.; Alcobia, Diana C.; White, Carl W.; Peach, Chloe J.; Glenn, Jackie R.; Zimmerman, Kris; Kondrashov, Alexander; Pfleger, Kevin D.G.; Friedman Ohana, Rachel; Robers, Matthew B.; Wood, Keith V.; Sloan, Erica K.; Woolard, Jeanette; Hill, Stephen J.

Abstract

Vascular endothelial growth factor (VEGF) is an important mediator of endothelial cell proliferation and angiogenesis via its receptor VEGFR2. A common tumor associated with elevated VEGFR2 signaling is infantile hemangioma that is caused by a rapid proliferation of vascular endothelial cells. The current first-line treatment for infantile hemangioma is the β-adrenoceptor antagonist, propranolol, although its mechanism of action is not understood. Here we have used bioluminescence resonance energy transfer and VEGFR2 genetically tagged with NanoLuc luciferase to demonstrate that oligomeric complexes involving VEGFR2 and the β2-adrenoceptor can be generated in both cell membranes and intracellular endosomes. These complexes are induced by agonist treatment and retain their ability to couple to intracellular signaling proteins. Furthermore, coupling of β2-adrenoceptor to β-arrestin2 is prolonged by VEGFR2 activation. These data suggest that protein-protein interactions between VEGFR2, the β2-adrenoceptor, and β-arrestin2 may provide insight into their roles in health and disease.

Citation

Kilpatrick, L. E., Alcobia, D. C., White, C. W., Peach, C. J., Glenn, J. R., Zimmerman, K., Kondrashov, A., Pfleger, K. D., Friedman Ohana, R., Robers, M. B., Wood, K. V., Sloan, E. K., Woolard, J., & Hill, S. J. (2019). Complex formation between VEGFR2 and the β2-adrenoceptor. Cell Chemical Biology, 26(6), 830-841.e9. https://doi.org/10.1016/j.chembiol.2019.02.014

• Journal Article Type: Article
• Acceptance Date: Feb 24, 2019
• Online Publication Date: Apr 4, 2019
• Publication Date: Jun 20, 2019
• Deposit Date: Mar 4, 2019
• Publicly Available Date: Apr 5, 2020
• Journal: Cell Chemical Biology
• Electronic ISSN: 2451-9456
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 26
• Issue: 6
• Pages: 830-841.e9
• DOI: https://doi.org/10.1016/j.chembiol.2019.02.014
• Keywords: VEGFR2; β2-adrenoceptors; Ligand binding; BRET; NanoBRET; Receptor oligomerization; β-arrestin; CRISPR/Cas9
• Public URL: https://nottingham-repository.worktribe.com/output/1602383
• Publisher URL: https://www.sciencedirect.com/science/article/pii/S2451945619300698
• Contract Date: Mar 4, 2019